Assembling, reviewing, and synthesizing state-of-the-art information on translational research and therapies of melanoma into one convenient source, Melanoma: Translational Research and Emerging Therapies provides clinicians and researchers the necessary context and perspective to intergrate and effectively deploy cutti
Assembling, reviewing, and synthesizing state-of-the-art information on translational research and therapies of melanoma into one convenient source, Melanoma: Translational Research and Emerging Therapies provides clinicians and researchers the necessary context and perspective to intergrate and effectively deploy cuttiHinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
SANJIV S. AGARWALA, M.D. is Chief of Medical Oncology and Hematology, Saint Luke's Cancer Center, Bethlehem, Pennsylvania, USA. Dr. Agarwala is an internationally recognized investigator in the field of melanoma and immunotherapy and has led numerous clinical trials of immunotherapy and targeted therapy in melanoma. He has authored or contributed to more than 130 publications and has served on the editorial boards of several journals including the Journal of Clinical Oncology and American Journal of Oncology Review. Dr. Agarwala is also a member of the Melanoma Core Committee of the Eastern Cooperative Oncology Group. VERNON K. SONDAK, M.D. is Chief of the Division of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA. Dr. Sondak is an internationally renowned surgical oncologist specializing in melanoma and other cutaneous malignancies, and has led clinical trials in surgical management and adjuvant vaccine therapy in melanoma. He is the Chair of the Melanoma Committee of the Southwest Oncology Group, and has authored or coauthored more than 170 peer-reviewed publications and invited review articles, and has edited three previous textbooks. He has served on the editorial boards of several journals, including the Annals of Surgical Oncology and the Journal of Clinical Oncology, and was Section Editor for Melanoma for Cancer for seven years.
Inhaltsangabe
1. UV radiation in melanoma development and pathogenesis. 2. Overview of molecular pathways in melanoma. 3. CHALLENGING MELANOCYTIC NEOPLASMS: SPITZOID MELANOMA VERSUS SPITZ NEVUS. 4. Melanoma genomics: Techniques and implications for therapy. 5. Ras signaling in melanoma development and prevention. 6. Targeting BRAF activity as a novel paradigm for melanoma therapy. 7. Therapeutic targeting of the melanoma stem cell population. 8. Pigmentation pathways and Microphtalmia-Associated Transcription Factor as new targets in melanoma. 9. Understanding interferon: Translating biologic advances into clinical progress. 10. Interferon and autoimmunity. 11. New approaches for optimizing melanoma vaccines. 12. Adoptive T cell immunotherapy. 13. Procurement of human melanoma specimens for translational research: Practical and legal considerations. Glossary of clinical and scientific terms.
1. UV radiation in melanoma development and pathogenesis. 2. Overview of molecular pathways in melanoma. 3. CHALLENGING MELANOCYTIC NEOPLASMS: SPITZOID MELANOMA VERSUS SPITZ NEVUS. 4. Melanoma genomics: Techniques and implications for therapy. 5. Ras signaling in melanoma development and prevention. 6. Targeting BRAF activity as a novel paradigm for melanoma therapy. 7. Therapeutic targeting of the melanoma stem cell population. 8. Pigmentation pathways and Microphtalmia-Associated Transcription Factor as new targets in melanoma. 9. Understanding interferon: Translating biologic advances into clinical progress. 10. Interferon and autoimmunity. 11. New approaches for optimizing melanoma vaccines. 12. Adoptive T cell immunotherapy. 13. Procurement of human melanoma specimens for translational research: Practical and legal considerations. Glossary of clinical and scientific terms.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826